-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, Watson Pharmaceuticals issued an announcement stating that as his term of office expires on November 15, Gao Xuemin will no longer serve as independent director of the company’s second board of directors and chairman of the second board’s nomination committee, and his resignation will be in Effective from the day when the company’s general meeting of shareholders elects new independent directors
.
In addition, the company held the 26th meeting of the second board of directors on November 16 and reviewed and approved the "Proposal on By-election of Independent Directors", and agreed to nominate Li Hui as an independent director candidate for the second board of directors.
From the date of review and approval by the company's general meeting of shareholders to the date of expiry of the second term of the board of directors
.
After being appointed as an independent director by the company's shareholders meeting, Ms.
Li Hui, female, born in July 1967, PhD
.
He was a lecturer at Jiangxi University of Traditional Chinese Medicine, an associate professor at Beijing Normal University, an associate researcher at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, and he is currently a researcher at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, director of the Center for Chinese Materia Medica, Ph.
